

Atantares



Headquarters: Suzhou, China

Sector: Life Science/Healthcare/Semiconductor

Stage & Funding Type: Series A; Private, last valued at ~ \$100 M

Problem: The advancement of AI in life sciences is held back by the prohibitively high cost of DNA synthesis, which severely limits the throughput of biological experiments.

Solution: Proprietary silicon-powered DNA synthesis platform with unique high-density chip, miniaturizing traditional mm level plate-based chemical synthesis reactions down to μm level, promoting an exponential reduction in the cost of DNA synthesis.

Market Opportunity: DNA synthesis is the key enabling technology for life sciences with TAM of \$ 4.6 B and CAGR of 31%.

Traction:

- CRO services: Serving over 400 clients across drug discovery, synthetic biology, diagnostics, DNA data storage and more.
- Synthesis instrument: World's only commercially available chip-based high-throughput oligo synthesizer, installed at 5 academic institutions.

Snapshot of Lead / Notable Investors:

- Prosperity 7, Frees Fund, Qiming Venture Partners, Alibaba Health, Fosun Health Capital, Asia Green Fund.

Team: Xin Zhao (Co-Founder & CEO), Dan Wu (Co-Founder & CTO), Yiming Dong (Co-Founder & CSO), with an interdisciplinary team that brings together expertise in integrated circuit design, semiconductor processing, microfluidics, instrumentation, chemistry, biology, bioinformatics and more.

Funding Ask: Seeking **\$15 M** to accelerate global market expansion and R&D for next generation chip-based gene synthesis.

Contact Information: Xin Zhao, CEO – xin.zhao@atantares.com/ Investor Relations: xi.he@atantares.com

